Peritoneal tuberculosis due to multidrug-resistant Mycobacterium tuberculosis

Susanna Esposito, Samantha Bosis, Lorena Canazza, Rossana Tenconi, Maurizio Torricelli, Nicola Principi

Research output: Contribution to journalArticlepeer-review


The emergence of drug-resistant Mycobacterium tuberculosis has been widely reported throughout the world, but there are very few data regarding children. We describe the case of a 14-year-old Peruvian adolescent who had been living in Italy since the age of 8 years and was diagnosed as having peritoneal tuberculosis (TB). While she was receiving first-line anti-TB therapy, she developed pyrazinamide-associated thrombocytopenia and cultures revealed a multidrug-resistant strain of Mycobacterium tuberculosis. Pyrazinamide, rifampicin and isoniazid were replaced by moxifloxacin, which was continued for 9 months together with ethambutol. The patient recovered without experiencing any drug-related adverse event or the recurrence of TB in the following year. In conclusion, this case illustrates some of the problems that can arise when multidrug-resistant TB has to be treated in children and adolescents, and also highlights the fact that further studies are needed to clarify which drugs should be used and for how long. Pediatrics International

Original languageEnglish
JournalPediatrics International
Issue number2
Publication statusPublished - Apr 2013


  • moxifloxacin
  • multidrug-resistant Mycobacterium tuberculosis
  • off-label antibiotics
  • peritoneal tuberculosis
  • tuberculosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Peritoneal tuberculosis due to multidrug-resistant Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this